{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.27","upperLimit":"3.07","value":"1.28"},{"groupId":"OG001","lowerLimit":"1.25","upperLimit":"3.00","value":"1.30"},{"groupId":"OG002","lowerLimit":"1.02","upperLimit":"3.00","value":"1.25"},{"groupId":"OG003","lowerLimit":"1.70","upperLimit":"3.07","value":"1.80"},{"groupId":"OG004","lowerLimit":"1.75","upperLimit":"3.93","value":"1.82"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.25","upperLimit":"2.00","value":"1.33"},{"groupId":"OG001","lowerLimit":"1.25","upperLimit":"1.25","value":"1.25"},{"groupId":"OG002","lowerLimit":"1.22","upperLimit":"43.27","value":"1.25"},{"groupId":"OG003","lowerLimit":"1.37","upperLimit":"3.52","value":"1.92"},{"groupId":"OG004","lowerLimit":"1.75","upperLimit":"1.78","value":"1.77"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"Cycle 1 Day 22"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Participants received MORAb-066 0.1 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, participant's discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.","id":"OG000","title":"MORAb-066 0.1 mg/kg"},{"description":"Participants received MORAb-066 0.3 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.","id":"OG001","title":"MORAb-066 0.3 mg/kg"},{"description":"Participants received MORAb-066 1 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant's discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.","id":"OG002","title":"MORAb-066 1 mg/kg"},{"description":"Participants received MORAb-066 2 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant's discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.","id":"OG003","title":"MORAb-066 2 mg/kg"},{"description":"Participants received MORAb-066 3 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.","id":"OG004","title":"MORAb-066 3 mg/kg"}],"paramType":"MEDIAN","populationDescription":"The PK analysis set was the group of participants who had sufficient PK data to derive at least one PK parameter. Here, \"Number analyzed\" signifies participants evaluable at a given time points for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Days 1 and 22: 0-168 hours post-dose (Cycle length=28 days)","title":"Tmax: Time to Reach Maximum Serum Concentration for MORAb-066","type":"SECONDARY","unitOfMeasure":"hours"}